Sakar Healthcare Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Sakar Healthcare te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	17.9%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Mar 23

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Mar 02

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Feb 08

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Jan 10

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Dec 14

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Nov 22

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Sakar Healthcare onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NSEI:SAKAR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2024	1,650	124	-55	488	N/A
6/30/2024	1,555	112	N/A	N/A	N/A
3/31/2024	1,542	117	-351	245	N/A
12/31/2023	1,518	125	N/A	N/A	N/A
9/30/2023	1,480	144	-475	163	N/A
6/30/2023	1,438	127	N/A	N/A	N/A
3/31/2023	1,342	128	-489	333	N/A
12/31/2022	1,302	178	N/A	N/A	N/A
9/30/2022	1,265	139	-568	352	N/A
6/30/2022	1,265	144	N/A	N/A	N/A
3/31/2022	1,291	152	-109	246	N/A
12/31/2021	1,139	80	N/A	N/A	N/A
9/30/2021	1,109	97	-284	368	N/A
6/30/2021	1,054	118	N/A	N/A	N/A
3/31/2021	953	107	-210	146	N/A
12/31/2020	913	118	N/A	N/A	N/A
9/30/2020	870	122	-219	-50	N/A
6/30/2020	884	106	N/A	N/A	N/A
3/31/2020	839	96	55	189	N/A
12/31/2019	851	88	N/A	N/A	N/A
9/30/2019	844	86	N/A	N/A	N/A
6/30/2019	744	78	N/A	N/A	N/A
3/31/2019	688	67	-88	161	N/A
3/31/2018	534	38	N/A	53	N/A
3/31/2017	447	34	N/A	20	N/A
3/31/2016	414	22	N/A	92	N/A
12/31/2015	386	24	N/A	38	N/A
3/31/2015	350	18	N/A	42	N/A
3/31/2014	297	18	N/A	86	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van SAKAR boven de spaarquote ( 6.7% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van SAKAR naar verwachting sneller zal groeien dan de markt Indian

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van SAKAR naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van SAKAR naar verwachting sneller zal groeien dan de markt Indian.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van SAKAR naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SAKAR naar verwachting over 3 jaar hoog zal zijn

Sakar Healthcare Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Second quarter 2025 earnings released: EPS: ₹2.17 (vs ₹1.68 in 2Q 2024)

New minor risk - Shareholder dilution

First quarter 2025 earnings released: EPS: ₹1.10 (vs ₹1.46 in 1Q 2024)

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2024

Full year 2024 earnings released: EPS: ₹5.64 (vs ₹6.86 in FY 2023)

Investor sentiment deteriorates as stock falls 15%

Third quarter 2024 earnings released: EPS: ₹0.98 (vs ₹2.16 in 3Q 2023)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Second quarter 2024 earnings released: EPS: ₹1.68 (vs ₹1.01 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 20%

New major risk - Financial position

First quarter 2024 earnings released: EPS: ₹1.46 (vs ₹1.65 in 1Q 2023)

New major risk - Share price stability

Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 27%

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2023

Full year 2023 earnings released: EPS: ₹6.59 (vs ₹8.90 in FY 2022)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Third quarter 2023 earnings released: EPS: ₹2.16 (vs ₹0.07 in 3Q 2022)

Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Investor sentiment improved over the past week

Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: ₹1.01 (vs ₹1.44 in 2Q 2022)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.65 (vs ₹1.80 in 1Q 2022)

Sakar Healthcare Limited, Annual General Meeting, Sep 20, 2022

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Full year 2022 earnings released: EPS: ₹8.73 (vs ₹7.09 in FY 2021)

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹1.44 (vs ₹3.04 in 2Q 2021)

Full year 2021 earnings released: EPS ₹7.09 (vs ₹6.43 in FY 2020)

Investor sentiment deteriorated over the past week

With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹6.87 (vs ₹6.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Third quarter 2021 earnings released: EPS ₹1.20 (vs ₹1.48 in 3Q 2020)

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

New 90-day high: ₹107

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Market bids up stock over the past week

New 90-day high: ₹91.65

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

First half earnings released

Market pulls back on stock over the past week

New 90-day high: ₹84.85

New 90-day high - ₹78.70

First quarter earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven